Infective Endocarditis: Diagnosis and Treatment

Raman Nohria, MD
Andrew Romaine, MD
Gabryel Garcia-Sampson, MD, MPH

American Family Physician. 2026;113(2):145-152.

Author disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Infective endocarditis develops when aggravating conditions damage the endothelial lining of the heart and create a nidus of infection. The nidus triggers a cytokine-mediated inflammatory response, which can lead to platelet aggregation and thrombus formation. Bacteria or fungi in the blood can then adhere to the thrombus and colonize, proliferate, and form vegetations. Staphylococcus aureus, Streptococcus species, and Enterococcus species comprise more than 80% of identified bacterial pathogens in cases of infective endocarditis. Endocarditis should be considered in any patient with fever or sepsis of unknown origin. Fever is the most common presenting feature in acute endocarditis, although it is uncommon in subacute cases. New or worsening heart murmur is a typical feature. Initial evaluation includes obtaining blood cultures and echocardiography. Use of the 2023 Duke Criteria is recommended to confirm diagnosis. Empiric intravenous antimicrobial therapy, infectious source control, and expert consultation from a multi-disciplinary team are the mainstays of initial treatment. Patients should also be monitored for surgical indications and development of complications. Patients with a history of endocarditis may benefit from antibiotic prophylaxis before certain procedures and should be counseled on the importance of maintaining oral and skin hygiene to reduce risk.

RAMAN NOHRIA, MD, is an assistant professor in the Department of Family Medicine and Community Health at the Duke University School of Medicine, Durham, North Carolina.

ANDREW ROMAINE, MD, is an assistant professor in the Department of Family Medicine and Community Health at the Duke University School of Medicine, Durham.

GABRYEL GARCIA-SAMPSON, MD, MPH, is a medical instructor in the Department of Family Medicine and Community Health at the Duke University Health System, Durham.

Address correspondence to Raman Nohria, MD, at raman.nohria@duke.edu.

Author disclosure: No relevant financial relationships.

  1. 1.Aluru JS, Barsouk A, Saginala K, et al. Valvular heart disease epidemiology. Med Sci (Basel). 2022;10(2):32.
  2. 2.Chen H, Zhan Y, Zhang K, et al. The global, regional, and national burden and trends of infective endocarditis from 1990 to 2019: results from the Global Burden of Disease Study 2019. Front Med (Lausanne). 2022;9:774224.
  3. 3.Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77(4):e25-e197.
  4. 4.Becher PM, Goßling A, Fluschnik N, et al. Temporal trends in incidence, patient characteristics, microbiology and in-hospital mortality in patients with infective endocarditis: a contemporary analysis of 86,469 cases between 2007 and 2019. Clin Res Cardiol. 2024;113(2):205-215.
  5. 5.Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EUROENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222-3232.
  6. 6.Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042.
  7. 7.Hubers SA, DeSimone DC, Gersh BJ, et al. Infective endocarditis: a contemporary review. Mayo Clin Proc. 2020;95(5):982-997.
  8. 8.Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: a review. JAMA. 2018;320(1):72-83.
  9. 9.Chambers HF, Bayer AS. Native-valve infective endocarditis. N Engl J Med. 2020;383(6):567-576.
  10. 10.Thornhill MH, Jones S, Prendergast B, et al. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. Eur Heart J. 2018;39(7):586-595.
  11. 11.Thompson GR, Jenks JD, Baddley JW, et al. Fungal endocarditis: pathophysiology, epidemiology, clinical presentation, diagnosis, and management. Clin Microbiol Rev. 2023;36(3):e0001923.
  12. 12.Li M, Kim JB, Sastry BKS, et al. Infective endocarditis. Lancet. 2024;404(10450):377-392.
  13. 13.Ziegler R, Arnold H, Bertram R, et al. Microbiologic diagnostics and pathogen spectrum in infective endocarditis of surgically treated patients: a five-year, retrospective, monocentric study. Infection. 2023;51(5):1523-1530.
  14. 14.Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435-1486.
  15. 15.Rasmussen M, Gilje P, Fagman E, et al. Bacteraemia with gram-positive bacteria—when and how do I need to look for endocarditis? Clin Microbiol Infect. 2024;30(3):306-311.
  16. 16.Schranz A, Barocas JA. Infective endocarditis in persons who use drugs: epidemiology, current management, and emerging treatments. Infect Dis Clin North Am. 2020;34(3):479-493.
  17. 17.Marks LR, Nolan NS, Liang SY, et al. Infectious complications of injection drug use. Med Clin North Am. 2022;106(1):187-200.
  18. 18.Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: updating the modified Duke Criteria. Clin Infect Dis. 2023;77(4):518-526.
  19. 19.McDonald EG, Aggrey G, Aslan AT, et al. Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines group consensus statement. JAMA Netw Open. 2023;6(7):e2326366.
  20. 20.Bai AD, Steinberg M, Showler A, et al. Diagnostic accuracy of transthoracic echocardiography for infective endocarditis findings using transesophageal echocardiography as the reference standard: a meta-analysis. J Am Soc Echocardiogr. 2017;30(7):639-646.e8.
  21. 21.Shively BK, Gurule FT, Roldan CA, et al. Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis. J Am Coll Cardiol. 1991;18(2):391-397.
  22. 22.Pedersen WR, Walker M, Olson JD, et al. Value of transesophageal echocardiography as an adjunct to transthoracic echocardiography in evaluation of native and prosthetic valve endocarditis. Chest. 1991;100(2):351-356.
  23. 23.Goehringer F, Lalloué B, Selton-Suty C, et al. Compared performance of the 2023 Duke-International Society for Cardiovascular Infectious Diseases, 2000 Modified Duke, and 2015 European Society of Cardiology Criteria for the Diagnosis of Infective Endocarditis in a French multicenter prospective cohort. Clin Infect Dis. 2024;78(4):937-948.
  24. 24.Moisset H, Rio J, Benhard J, et al. Evaluation of the specificity of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Classification for Infective Endocarditis. Clin Infect Dis. 2024;78(4):930-936.
  25. 25.Papadimitriou-Olivgeris M, Monney P, Frank M, et al. Evaluation of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Criteria in a multicenter cohort of patients with suspected infective endocarditis. Clin Infect Dis. 2024;78(4):949-955.
  26. 26.van der Vaart TW, Prins JM, Soetekouw R, et al. Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2022;74(8):1442-1449.
  27. 27.Kaura A, Byrne J, Fife A, et al. Inception of the ‘endocarditis team’ is associated with improved survival in patients with infective endocarditis who are managed medically: findings from a before-and-after study. Open Heart. 2017;4(2):e000699.
  28. 28.Chirillo F, Scotton P, Rocco F, et al. Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis. Am J Cardiol. 2013;112(8):1171-1176.
  29. 29.Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415-424.
  30. 30.Barda B, Schindler C, Bernasconi E, et al. Breaking the dogma of intravenous treatment for infective endocarditis: a systematic review and meta-analysis. J Clin Med. 2024;13(24):7518.
  31. 31.Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996;101(1):68-76.
  32. 32.Stamboulian D, Bonvehi P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis. 1991;13(suppl 2):S160-S163.
  33. 33.Park LP, Chu VH, Peterson G, et al.; International Collaboration on Endocarditis (ICE) Investigators. Validated risk score for predicting 6-month mortality in infective endocarditis. J Am Heart Assoc. 2016;5(4):e003016.
  34. 34.Hammond-Haley M, Hartley A, Al-Khayatt BM, et al. Trends in the incidence and mortality of infective endocarditis in high-income countries between 1990 and 2019. Int J Cardiol. 2023;371:441-451.
  35. 35.Herrick KR, Terrio JM, Herrick C. Medical clearance for common dental procedures. Am Fam Physician. 2021;104(5):476-483.
  36. 36.Pierce D, Calkins BC, Thornton K. Infectious endocarditis: diagnosis and treatment. Am Fam Physician. 2012;85(10):981-986.
  37. 37.Giessel BE, Koenig CJ, Blake RL. Management of bacterial endocarditis. Am Fam Physician. 2000;61(6):1725-1732.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.